Data for the Common Good’s Post

Follow-up strategies for cancer should be personalized based on risk for recurrence and patient preferences. To avoid low value care and costs.

The recently published randomized controlled ENSURE trial offers important insights into follow-up care for early-stage endometrial cancer. It revealed that patients who received reduced follow-up schedules were more often satisfied with their follow-up care. This highlights an important point: intensive follow-up schedules can sometimes lead to low-value care, offering minimal benefits to patients while increasing costs and wasting resources 📈 In our clinical commentary, we explore the broader implications of these findings for follow-up practices in common gynecologic cancers. We emphasize that sometimes "less is more" and advocate for greater personalization in follow-up care 📖 Read more about our insights and recommendations in Gynecologic Oncology (Society of Gynecologic Oncology) using this link: https://lnkd.in/dsdfyZnD A huge thank you to my coauthors for their expertise and collaboration on this work! M.Caroline Vos, Luc van Lonkhuijzen, Lonneke van de Poll-Franse, Nicole Ezendam #SurvOnc #HealthcareInnovation #PatientCenteredCare

Intensive follow-up after gynecologic cancers can lead to low-value care. Sometimes less is more! Risk-based, personalized follow-up strategies are key to improving outcomes💡 Check out our commentary in Gynecologic Oncology (Society of Gynecologic Oncology) — free access ends in a few days! #SurvOnc #HealthcareInnovation #PatientCenteredCare

Here's a good overview from the top voices in organoid research. Topics include: • Heart-on-a-chip • Intestinal organoids • Lung models • Liver organoids • Trophoblast models • Bone models • Cancer models • Bioprinting

FGFR inhibitors for #bladdercancer #urothelialcarcinoma (UC): In our editorial in European Urology, Vadim Koshkin University of California, San Francisco and I highlight the current niche for these drugs in the treatment of FGFR3 mutation/fusion+ patients, as well as their potential future role in the therapeutic landscape- Key points are 1) Erdafitinib is a pan-FGFR inhibitor approved for advanced UC following prior PD1/L1 inhibition therapy; Toxicities are manageable with prompt attention and patient education, 2) FGFR3-specific inhibitors are being developed to potentially provide a better therapeutic index, 3) combination with PD1 inhibition or EV appears feasible and may provide incremental activity; other novel tolerable combinations and settings warrant evaluation with innovative strategies in the context of rapidly changing therapeutic landscape, 4) Development of FGFR inhibitors for earlier stages is ongoing, notably prolonged intravesical delivery using an innovative pretzel-shaped device (TAR-210) for non-muscle-invasive bladder cancer (NMIBC) with FGFR3 alterations- glad to comment from AdventHealth Central Florida #cancer Institute

Our recently published manuscript in Cancer Cell is out – Diffuse hemispheric glioma, H3G34R/V-mutant (H3G34-DHG) - https://lnkd.in/ei24sP_A I want to thank all our collaborators, including lab mates at Filbin Lab (Dana-Farber Cancer Institute), Mariella Filbin and Chris Jones lab for always believing in our work with perseverance. I want to extend a special appreciation to our co-leads, Ilon Liu, Lynn Bjerke, and Rebecca Rogers. 🔬 Key Insight: H3G34-DHG, a lethal brain tumor, shows similar patterns to developing interneurons. 🧩 🧬 Findings: Tumor Origin: H3G34-DHG tumors may derive from interneuronal precursors with GABAergic traces🧠 Cellular Hierarchy: Tumors mimic the spatial organization of progenitor cells in the developing brain. 🧪 CRISPR Screens: Identified genes crucial for tumor growth, with CDK6 being a major vulnerability. 🔬 💊 Therapeutic Insights: CDK4/6 Inhibitors and CDK6-Specific Degrader: 1.    H3G34-DHG tumor cells are more sensitive to these small molecules compared to other pediatric high-grade glioma subtypes. 2.    Promotes partial differentiation in H3G34-DHG tumor cells, reducing growth and extending survival. ⏳ 🩺 Clinical Impact: We report a refractory patient with DHG-H3G34 experienced 17 months of stable disease on a CDK4/6 inhibitor. 🎯 🔍 Conclusion: Targeting CDK6 offers a promising new therapeutic avenue for treating H3G34-DHG 🌟 A final thanks to the Alex Lemonade Stand Foundation (@ALSF) “A” Award and Young Investigator, NIH Innovator Award (DP2), Sontag Foundation for funding this work #Glioma #CancerResearch #NeuroOncology #CDK6 #TherapeuticTarget

⚠️ Attention Clinical researchers and Bioinformaticians! Tomorrow, #canSERV_EU 🎗️partner Euro-BioImaging is organising a Virtual Pub on 🎗️Preparing for Clinical Translation: Guidelines for Validating and Reporting Algorithm Performance in Biomedical Imaging Analysis ⭐ 🗓️ June 28, 2024 13.00 CEST ➡️https://lnkd.in/e8Rx3u_A #AI #biomedicalimageanalysis #algorithmvalidation #clinicaltranslation

Did you know that cancer is the second leading cause of death worldwide (Lee, 2019)? Being diagnosed with cancer can change a patient's life and be challenging physically and emotionally for them (Lee, 2019). It has been studied that spirituality can impact and improve cancer patient's quality of life and decrease feelings of anxiety, depression, and distress for these patients (Lee, 2019). Cancer patients report that spirituality is a coping mechanism that helps them generate strength (Lee, 2019). Culturally appropriate spiritual care may be beneficial for cancer patients and should be provided (Lee, 2019). References Lee, Y. (2019). Spiritual care for cancer patients. Asia-Pacific Journal of Oncology Nursing, 6(2), 101–103. https://lnkd.in/eHw5USrm

🧠 Is Automatic Tumor Segmentation on Whole-Body 18F-FDG PET Images a Clinical Reality? 🧠 This is the title of the latest article by one of the creator of the open-source MOOSE (Multi-Organ Objective SEgmentation) software. His answer in short: Not yet, but we're close! Here's why: ✅ Significant AI advancements in tumor segmentation ✅ Growing clinical interest, especially in lymphoma management ✅ Progress in both academic research and commercial tools But challenges remain: ❗ Generalizability across cancer types and imaging systems ❗ Need for large-scale validation studies ❗ Regulatory hurdles for AI in healthcare ❗ Limited availability of comprehensive PET datasets The key? Seamless clinical integration and increased collaboration across academia, clinics, and industry. 🔗 MOOSE 2.0 framework: https://lnkd.in/eeNRG9jk 📄 Original article: https://lnkd.in/ecwMwBRW #NuclearMedicine #AI #OncologyImaging #PET_CT #MOOSE

The Systematic Review on RF-EMF Exposure and Cancer by Karipidis et al. (2024) has Serious Flaws that Undermine the Validity of the Study’s Conclusions Five key weaknesses of the Karipidis et al. (2024) SR: 1. Basing conclusions on studies with Flawed Designs 2. Excessive Reliance on RF-EMF exposure Categories that do not reflect extent of exposure 3. Mischaracterization of the evidence on brain cancer Time-Trends 4. Understatement of the Considerable uncertainty about cancer risk after longer latent periods following exposure 5. Failure to follow widely used scientific guidance for systematic Reviews and Meta-Analyses #RFEMF #Exposure #Cancer #CellPhones #MobilePhones #Radiofrequency